Equities
Health CareMedical Equipment and Services
  • Price (EUR)72.50
  • Today's Change2.30 / 3.28%
  • Shares traded107.83k
  • 1 Year change-9.38%
  • Beta0.9716
Data delayed at least 15 minutes, as of Dec 01 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gerresheimer AG is a Germany-based company that is active in the pharmaceuticals and health care industry. It operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.

  • Revenue in EUR (TTM)1.72bn
  • Net income in EUR90.56m
  • Incorporated2007
  • Employees10.94k
  • Location
    Gerresheimer AGKlaus-Bungert-Strasse 4DUESSELDORF 40468GermanyDEU
  • Phone+49 211618100
  • Fax+49 2 116181295
  • Websitehttps://www.gerresheimer.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tarkett SA3.09bn27.40m802.34m12.01k29.170.79934.580.25920.41960.419647.4015.311.194.339.49257,736.501.070.41171.710.562519.3722.810.90150.33840.79355.440.4774165.516.050.3826179.06-33.78-4.55--
Essentra PLC753.32m9.73m852.87m8.33k88.121.638.551.130.0277-0.59022.161.490.5133--3.9678,083.340.81321.761.212.22----1.582.461.213.190.4919191.27-33.37-9.77854.55---2.24-21.94
James Halstead PLC338.15m46.72m948.80m819.0020.314.9117.332.810.09680.09680.70030.40031.16--6.20356,361.4016.0017.2123.3724.07--41.4713.8214.551.18267.990.03372.559.573.921.172.01-5.163.58
Uponor Oyj1.44bn103.00m1.07bn4.20k10.302.226.440.74581.421.4219.856.611.454.605.84339,867.8011.529.0819.2614.7136.8235.357.956.481.08--0.163757.5315.603.629.3718.31-2.147.81
Forbo Holding AG1.32bn140.19m1.67bn5.74k11.832.638.471.2793.8693.86885.76422.581.213.055.05234,671.0012.8510.6818.4614.2934.8337.5610.638.990.8428--0.202330.3812.191.1332.962.05-0.60735.64
Gerresheimer AG1.72bn90.56m2.20bn10.94k24.341.718.541.282.882.8854.9241.040.54944.276.68165,073.003.053.374.294.7329.9229.635.566.270.48247.800.515643.495.581.72-5.397.6612.963.55
Daetwyler Holding AG913.45m108.29m2.30bn8.68k28.918.34--2.526.2810.4152.9421.750.72213.683.97132,138.108.569.5414.3812.2224.0025.8211.8511.280.5127--0.661147.7615.10-4.8617.5916.526.5413.81
Trelleborg AB2.56bn290.85m5.64bn21.84k21.321.7813.402.2011.9218.05104.78142.660.46383.254.321,281,960.005.264.386.495.6035.5732.9111.347.350.850525.820.281641.74-21.38-2.601.964.11-1.865.29
Data as of Dec 01 2022. Currency figures normalised to Gerresheimer AG's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.